Chargement en cours...

Pharmacological LRRK2 kinase inhibition induces LRRK2 protein destabilization and proteasomal degradation

Leucine-rich repeat kinase 2 (LRRK2) kinase activity is increased in several pathogenic mutations, including the most common mutation, G2019S, and is known to play a role in Parkinson’s disease (PD) pathobiology. This has stimulated the development of potent, selective LRRK2 kinase inhibitors as one...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Sci Rep
Auteurs principaux: Lobbestael, E., Civiero, L., De Wit, T., Taymans, J.-M., Greggio, E., Baekelandt, V.
Format: Artigo
Langue:Inglês
Publié: Nature Publishing Group 2016
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5034242/
https://ncbi.nlm.nih.gov/pubmed/27658356
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep33897
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!